News >

MRD Assessment Gains Momentum in Hematologic Malignancies

Ellie Leick
Published: Friday, Apr 03, 2020

Dr Jerald P. Radich

Jerald P. Radich, MD

Measurable residual disease (MRD) serves as an important biomarker to determine how a patient with a hematologic malignancy is responding to treatment, according to Jerald P. Radich, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication